Global Partner to Pharma,
Biotech and Healthcare

Global Partner to Pharma & Biotech

Mawdsleys Specialty Pharma (MSP) partners with Pharma & Biotech companies to deliver pre-license named patient programmes, registration and commercialisation of pharma products.

Product licensing: we offer a full turnkey product registration and market access service for pharmaceutical and biotech companies in our core territories of UK, Brazil and Israel.

Named Patient Programmes: working with pharmaceutical companies and healthcare providers, to provide physicians and patients access (in accordance with regulatory requirements) to medicines not approved in their home country, through a fully managed offering.

30,000 shipments
to over 1,000 hospitals
in 6 continents each year

Named Patient Programmes
delivered into 47 countries
including 21 of EU 27

Working with
80+ Pharma &
Biotech partners

Regional focus
On EU
and LATAM

3 Global Offices

Product Licensing, Market Access and Named Patient Supply Delivered through our 3 Global Offices

Visit Country Website

Pharma Healthcare Service
Provider with a 200 year history

Founded in 1825, Mawdsleys is the largest independent supplier of both unlicensed and licensed medicines to the National Health Service. Mawdsleys has expanded its global presence with operations in Brazil and Israel and continues to develop into new territories internationally.

We have expertise in all areas of the pharmaceutical supply chain, from providing physicians and their patients access to unlicensed medicines and third party distribution, to in-licensing products in territories. Our global infrastructure and expertise in country-specific regulatory systems mean we are ideally placed to ensure patients all over the world get the medicines they need, when they need them.

Niche Pharmaceuticals
and Rare Genetic Diseases
are our fields of expertise.

Rare diseases affect a very small percentage of each population in a country, but most are associated with life-long disability, often starting in childhood. Many of these rare diseases are chronic, degenerative and potentially life-threatening conditions, often under-diagnosed or diagnosed too late. A supportive, dedicated framework has been set up in the USA, EMA and many others geographies to promote a greater understanding of these diseases, stimulate more public and private research and to encourage innovative biopharma companies to develop and make available breakthrough treatments for some of these diseases.

Access to these products can be complex, challenging and costly. For over 15 years, Mawdsleys has been the reference partner for many physicians and their patients to source the products patients need as quickly as possible whilst ensuring compliance with regulatory systems. With its well-established Unlicensed Medicines organisation in more than 52 countries (including Europe, Brazil, Israel), Mawdsleys Specialty Pharma has the expertise and resource to source niche medicines that are not licensed or readily available for the patients suffering from these rare diseases. In many cases, Mawdsleys Specialty Pharma is also able to help patients access funding for these important but costly medicines.

Countries we supply, source
and licence medicines for

Countries we operate in
- Albania
- Andorra
- Antigua and Barbuda
- Argentina
- Armenia
- Australia
- Austria
- Azerbaijan
- Bahamas
- Bahrain
- Bangladesh
- Barbados
- Belarus
- Belgium
- Belize
- Bhutan
- Bolivia
- Bosnia and Herzegovina
- Brazil
- Brunei
- Bulgaria
- Cambodia
- Canada
- Chile
- Colombia
- Costa Rica
- Croatia
- Cuba
- Cyprus
- Czech Republic
- Denmark
- Dominica
- Dominican Republic
- Ecuador
- El Salvador
- Estonia
- Fiji
- Finland
- France
- Georgia
- Germany
- Greece
- Grenada
- Guatemala
- Guyana
- Haiti
- Honduras
- Hungary
- Iceland
- Indonesia
- Iran
- Iraq
- Ireland
- Israel
- Italy
- Jamaica
- Japan
- Jordan
- Kiribati
- Kosovo
- Kuwait
- Laos
- Latvia
- Lebanon
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia (FYROM)
- Malaysia
- Maldives
- Malta
- Marshall Islands
- Mauritania
- Mexico
- Micronesia
- Moldova
- Monaco
- Mongolia
- Montenegro
- Myanmar (formerly Burma)
- Nauru
- Nepal
- Netherlands
- New Zealand
- Nicaragua
- North Korea
- Norway
- Oman
- Palau
- Palestine
- Panama
- Papua New Guinea
- Paraguay
- Peru
- Philippines
- Poland
- Portugal
- Qatar
- Romania
- Saint Kitts and Nevis
- Saint Lucia
- Saint Vincent and the Grenadines
- Samoa
- San Marino
- Saudi Arabia
- Serbia
- Singapore
- Slovakia
- Slovenia
- Solomon Islands
- South Africa
- South Korea
- Spain
- Sri Lanka
- Suriname
- Sweden
- Switzerland
- Syria
- Taiwan
- Thailand
- Timor-Leste
- Tonga
- Trinidad and Tobago
- Turkey
- Tuvalu
- Ukraine
- United Arab Emirates (UAE)
- United Kingdom (UK)
- Uruguay
- Vanuatu
- Vatican City (Holy See)
- Venezuela
- Vietnam
- Yemen
Supply
Source
License/Commercialise
In country operation
- Brazil
- Israel
- United Kingdom
Regeneration Capabilities
- Belize
- Costa Rica
- El Salvador
- Guatemala
- Honduras
- Nicaragua
- Panama
- Argentina
- Bolivia
- Chile
- Colombia
- Ecuador
- French Guiana
- Guyana
- Paraguay
- Peru
- Suriname
- Uruguay
- Venezuela
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Ireland
- Italy
- Latvia
- Lithuania
- Luxembourg
- Malta
- Netherlands
- Poland
- Portugal
- Romania
- Slovakia
- Slovenia
- Spain
- Sweden

Countries we supply, source
and licence medicines for

Supply
Source
License/Commercialise

Global Partner to Pharma, Biotech and Healthcare